All Curated Mutation Sites in HPV

The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HPV related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.

Browse Data by Virus Gene/Protein/Region, Disease OR Description

*Please select one option you are interested in, the page will be automatically redirected.

Virus Gene/Protein

Disease

Description

Click the button below to quickly view the viral genes/regions/protein for mutation

Show All

E1^E4

Keyword: Uterine Cervical Neoplasms-30930693

ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	30930693	7432_7433insG	LCR		Uterine Cervical Neoplasms	G R L	View
2	30930693	7861delA	LCR		Uterine Cervical Neoplasms	G R L	View
3	30930693	A7285C	LCR		Uterine Cervical Neoplasms	G R L	View
4	30930693	A7727C	LCR		Uterine Cervical Neoplasms	G R L	View
5	30930693	C24T	LCR		Uterine Cervical Neoplasms	G R L	View
6	30930693	C7268T	LCR		Uterine Cervical Neoplasms	G R L	View
7	30930693	G7191T	LCR		Uterine Cervical Neoplasms	G R L	View
8	30930693	G7518A	LCR		Uterine Cervical Neoplasms	G R L	View
9	30930693	G7839A	LCR		Uterine Cervical Neoplasms	G R L	View
10	30930693	T7199C	LCR		Uterine Cervical Neoplasms	G R L	View
11	30930693	T7447C	LCR		Uterine Cervical Neoplasms	G R L	View
12	30930693	T7711G	LCR		Uterine Cervical Neoplasms	G R L	View
13	30930693	A645C	E7	E7	Uterine Cervical Neoplasms	G R L	View
14	30930693	A646C	E7	E7	Uterine Cervical Neoplasms	G R L	View
15	30930693	A647G	E7	E7	Uterine Cervical Neoplasms	G R L	View
16	30930693	G666A	E7	E7	Uterine Cervical Neoplasms	G R L	View
17	30930693	L28F	E7	E7	Uterine Cervical Neoplasms	G R L	View
18	30930693	N29H	E7	E7	Uterine Cervical Neoplasms	G R L	View
19	30930693	N29S	E7	E7	Uterine Cervical Neoplasms	G R L	View
20	30930693	T760C	E7	E7	Uterine Cervical Neoplasms	G R L	View
21	30930693	T846C	E7	E7	Uterine Cervical Neoplasms	G R L	View
22	30930693	A131C	E6	E6	Uterine Cervical Neoplasms	G R L	View
23	30930693	A275G	E6	E6	Uterine Cervical Neoplasms	G R L	View
24	30930693	A276G	E6	E6	Uterine Cervical Neoplasms	G R L	View
25	30930693	A442C	E6	E6	Uterine Cervical Neoplasms	G R L	View
26	30930693	C168G	E6	E6	Uterine Cervical Neoplasms	G R L	View
27	30930693	C360A	E6	E6	Uterine Cervical Neoplasms	G R L	View
28	30930693	D25E	E6	E6	Uterine Cervical Neoplasms	G R L	View
29	30930693	D25N	E6	E6	Uterine Cervical Neoplasms	G R L	View
30	30930693	D25Q	E6	E6	Uterine Cervical Neoplasms	G R L	View
31	30930693	D64E	E6	E6	Uterine Cervical Neoplasms	G R L	View
32	30930693	E113D	E6	E6	Uterine Cervical Neoplasms	G R L	View
33	30930693	G176A	E6	E6	Uterine Cervical Neoplasms	G R L	View
34	30930693	I27R	E6	E6	Uterine Cervical Neoplasms	G R L	View
35	30930693	L83V	E6	E6	Uterine Cervical Neoplasms	G R L	View
36	30930693	N58D	E6	E6	Uterine Cervical Neoplasms	G R L	View
37	30930693	N58S	E6	E6	Uterine Cervical Neoplasms	G R L	View
38	30930693	T109C	E6	E6	Uterine Cervical Neoplasms	G R L	View
39	30930693	T178A	E6	E6	Uterine Cervical Neoplasms	G R L	View
40	30930693	T178G	E6	E6	Uterine Cervical Neoplasms	G R L	View
41	30930693	T183G	E6	E6	Uterine Cervical Neoplasms	G R L	View
42	30930693	T22S	E6	E6	Uterine Cervical Neoplasms	G R L	View
43	30930693	T295G	E6	E6	Uterine Cervical Neoplasms	G R L	View
44	30930693	T350G	E6	E6	Uterine Cervical Neoplasms	G R L	View
45	30930693	T86K	E6	E6	Uterine Cervical Neoplasms	G R L	View

Contents
Description

The table shows all curated mutation sites of HPV in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.